Share your story and shine at JK Monitor!🌟 Welcome to JK Monitor, where every story matters and every achievement is celebrated! We invite you to share the remarkable journey of your life and showcase your accomplishments to the world. Join our exclusive interviews that honor exceptional individuals just like you. JAMMU: Venus Remedies Limited (NSE: VENUSREM, BSE: 526953), a leading research-driven global pharmaceutical company, has joined the United Nations Global Compact (UNGC), the world’s largest corporate sustainability initiative. With this strategic move, the company aligns its operations and strategies with the UNGC’s Ten Principles on human rights, labour, environment, and anti-corruption.
Venus Remedies’ participation in the UNGC further validates its longstanding commitment to responsible healthcare innovation, ethical governance, and environmental stewardship. The company has implemented a comprehensive Environmental, Social and Governance (ESG) strategy across its international operations. In line with its climate accountability goals, it has obtained ISO 14064-1 certification for greenhouse gas emissions reporting, ensuring transparency in environmental performance and carbon management.
“At Venus Remedies, we believe in advancing science with a strong sense of responsibility,” said Ms. Aditi K. Chaudhary, President, International Business, Venus Remedies Ltd. “Our decision to join the United Nations Global Compact is a natural extension of our core values, where access, ethics, and excellence converge. This milestone not only enhances our global standing but also reaffirms our commitment to driving meaningful change. We view this as a deep responsibility to our global partners, the healthcare systems we support, and the shared future of our planet.”
As a UNGC participant, Venus Remedies will publish an annual Communication on Progress (CoP) to share updates on its sustainability performance and adherence to the Compact’s principles. This global affiliation marks a critical step in the company’s mission to create long-term value through ethical practices, scientific innovation, and inclusive healthcare delivery.
Further strengthening its role in public health, Venus Remedies has been a long-standing supplier of WHO-prequalified pharmaceuticals to international health agencies. In recent years, the company has secured key supply contracts with UNICEF for the essential antibiotic ceftriaxone, and with the Pan American Health Organization (PAHO) for critical oncology medications. These partnerships enhance the company’s impact in delivering vital medicines to underserved populations across Latin America, Africa, and Asia.
Aligned with its commitment to SDG 3 and its ESG-led innovation roadmap, Venus Remedies has made antimicrobial resistance (AMR) a cornerstone of its R&D agenda. The company recognizes AMR not only as a scientific challenge, but as a global sustainability issue—impacting health systems, food security, and environmental resilience. Its continued investment in this area reflects the holistic approach to sustainable global health that the UNGC promotes.
In the area of AMR, Venus Remedies continues to innovate through its critical care pipeline. The company’s novel polymyxin B formulation, VRP-034, has been granted Qualified Infectious Disease Product (QIDP) designation by the U.S. Food and Drug Administration under the GAIN (Generating Antibiotic Incentives Now) Act. This designation provides fast-track regulatory review and five additional years of market exclusivity post-approval, accelerating the delivery of next-generation antibiotics for drug-resistant infections.
Beyond product innovation, the company plays a key role in advancing AMR surveillance and global policy development. Its initiatives such as GASAR (Global Antimicrobial Surveillance and Resistance) help generate essential data on resistance patterns, while the PLEA Trust supports antibiotic stewardship through education and responsible use. Venus Remedies is also an active member of the AMR Industry Alliance, and contributes to cross-border collaboration on AMR strategy via the India AMR Innovation Hub and the Vivli AMR Register—initiatives that strengthen both public policy and clinical practice.
The company’s commitment to quality is reflected in its global manufacturing credentials. Venus Remedies holds Good Manufacturing Practice (GMP) approvals from several leading authorities, including EU-GMP (INFARMED), PIC/S members such as Malaysia and Ukraine, SAHPRA, UNICEF, TGA, INVIMA, and WHO-GMP. These are complemented by internationally recognized ISO certifications in quality management (ISO 9001), environmental management (ISO 14001), and occupational health and safety (ISO 45001), demonstrating its adherence to stringent global standards across facilities.
Over the years, Venus Remedies has established itself as a trusted partner to health systems worldwide. Its strategic collaborations with national regulators, international donors, and institutional buyers continue to amplify the company’s impact in delivering affordable and quality-assured therapeutics.
About Venus Remedies Ltd (venusremedies.com)
Panchkula-based Venus Remedies Ltd (NSE: VENUSREM, BSE: 526953) is among the 10 leading fixed-dosage injectable manufacturers in the world. Having a commercial presence in 90+ countries with a portfolio of 75 products spread over Europe, Australia, Africa, Asia-Pacific, Commonwealth States, the Middle East, Latin America and the Caribbean region, the company has nine globally benchmarked facilities in Panchkula, Baddi and Werne (Germany), apart from 11 overseas marketing offices. The company holds the GMP approvals from European- GMP (INFARMED), PIC/S (Malaysia & Ukraine), SAHPRA, UNICEF, TGA, INVIMA & WHO-GMP, alongside key ISO certifications for quality, environmental, and occupational health and safety management.
Central to its mission, Venus Remedies is a frontrunner in combating antimicrobial resistance (AMR) through its dedicated research division, Venus Medicine Research Centre (VMRC). The company is pivotal in developing advanced antibiotics and β-lactam/β-lactamase inhibitor combinations aimed at tackling multidrug-resistant pathogens. Its notable initiatives like GASAR provide essential data on antibiotic resistance, while the PLEA Trust fosters antibiotic stewardship. As an influential member of the AMR Industry Alliance, India AMR Innovation Hub, and Vivli AMR Registry, Venus Remedies shapes global AMR research and policy. Through strategic collaborations with academic and health organizations worldwide, the company enhances AMR surveillance and supports innovative drug development, affirming its leadership in global healthcare.